Industrial Alliance Investment Management Inc. Sells 6,280 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Industrial Alliance Investment Management Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 48.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,720 shares of the biopharmaceutical company’s stock after selling 6,280 shares during the quarter. Industrial Alliance Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $4,629,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 92.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,694,308 shares of the biopharmaceutical company’s stock valued at $1,001,556,000 after acquiring an additional 813,967 shares during the period. Renaissance Technologies LLC raised its holdings in Regeneron Pharmaceuticals by 108.3% during the 2nd quarter. Renaissance Technologies LLC now owns 583,062 shares of the biopharmaceutical company’s stock valued at $344,665,000 after acquiring an additional 303,200 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $136,678,000. FMR LLC raised its holdings in Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. FMR LLC now owns 10,176,199 shares of the biopharmaceutical company’s stock valued at $6,015,457,000 after acquiring an additional 193,175 shares during the period. Finally, Great West Life Assurance Co. Can bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $116,414,000. Institutional investors own 84.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on REGN. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $860.00 and gave the company an “overweight” rating in a report on Friday, February 17th. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $1,001.00 to $1,025.00 and gave the company an “outperform” rating in a report on Tuesday. SVB Leerink boosted their price target on shares of Regeneron Pharmaceuticals from $770.00 to $834.00 and gave the company a “market perform” rating in a research report on Monday, February 6th. EF Hutton Acquisition Co. I restated a “buy” rating and set a $853.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, February 24th. Finally, JPMorgan Chase & Co. upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 price target for the company in a research report on Friday, January 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $815.38.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $760.30 on Thursday. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $83.12 billion, a PE ratio of 19.88, a P/E/G ratio of 2.57 and a beta of 0.21. The firm has a fifty day simple moving average of $745.90 and a two-hundred day simple moving average of $727.42. Regeneron Pharmaceuticals, Inc. has a twelve month low of $538.01 and a twelve month high of $800.48.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last posted its quarterly earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share for the quarter, topping the consensus estimate of $8.18 by $4.38. The business had revenue of $3.41 billion during the quarter, compared to the consensus estimate of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The firm’s revenue for the quarter was down 31.1% on a year-over-year basis. During the same period in the previous year, the firm posted $23.72 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 34.22 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 739 shares of the business’s stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $764.50, for a total value of $564,965.50. Following the completion of the sale, the chief financial officer now directly owns 32,105 shares of the company’s stock, valued at $24,544,272.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 739 shares of the business’s stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $764.50, for a total value of $564,965.50. Following the completion of the sale, the chief financial officer now directly owns 32,105 shares of the company’s stock, valued at $24,544,272.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert E. Landry sold 752 shares of the company’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $788.88, for a total transaction of $593,237.76. Following the transaction, the chief financial officer now directly owns 32,105 shares of the company’s stock, valued at $25,326,992.40. The disclosure for this sale can be found here. Insiders sold 27,273 shares of company stock valued at $21,189,979 over the last three months. Insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.